

RESEARCH

Open Access



# Interaction between baseline HBV loads and the prognosis of patients with HCC receiving anti-PD-1 in combination with antiangiogenic therapy undergoing concurrent TAF prophylaxis

Xiaoyun Hu<sup>†</sup>, Rong Li<sup>†</sup>, Qi Li, Mengya Zang, Guosheng Yuan\* and Jinzhang Chen\*

## Abstract

**Background:** A high baseline hepatitis B virus (HBV) load has always been listed as an exclusion criterion for programmed cell death-1 (PD-1) inhibitor-associated therapy in clinical trials, as the interaction between HBV load and anti-PD-1/PD-L1 therapy with anti HBV therapy remains controversial.

**Methods:** We retrospectively enrolled 70 unresectable HCC patients who were seropositive for HBsAg and accepted tenofovir alafenamide fumarate (TAF) therapy before anti-PD-1 in combination with an antiangiogenic treatment. Patients were divided into a low HBV DNA group ( $\leq 2000$  IU/ml) and a high HBV DNA group ( $> 2000$  IU/ml) according to the baseline HBV DNA levels. Tumour response and progression-free survival (PFS) were compared, and univariate and multivariate Cox analyses were performed to identify potential risk factors for PFS. The incidences of HBV reactivation and HBV-associated hepatitis were also recorded.

**Results:** 48 patients were assigned to the low group and the remaining 22 patients were assigned to the high group. The objective response rates (ORRs), disease control rates (DCRs), and PFS between the two groups showed no significant difference ( $P = 0.761, 0.552, \text{ and } 0.784$ , respectively). The results of Cox analyses revealed that there was no relationship between baseline HBV load and PFS. Additionally, HBV reactivation occurred in only 2 patients (2.9%), and no patient experienced HBV-related hepatic impairment when given a continuous TAF treatment.

**Conclusions:** Baseline HBV loads do not affect the prognosis of HCC patients receiving anti-PD-1 in combination with an antiangiogenic therapy, while PD-1 inhibitors do not aggravate HBV reactivation and hepatic impairment in patients simultaneously subjected to TAF prophylaxis.

<sup>†</sup>Xiaoyun Hu and Rong Li contributed equally to this work.

\*Correspondence: guoshengyuan1991@163.com; chenjinzhang@smu.edu.cn

Department of Infectious Diseases and Hepatology Unit, Nanfang Hospital, Southern Medical University, 1,838 North Guangzhou Ave, Guangzhou 510515, Guangdong, China



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

## Key points

Baseline HBV loads do not affect the prognosis of HCC patients receiving anti-PD-1 in combination with antiangiogenic therapy. Besides, PD-1 inhibitors do not aggravate HBV reactivation and hepatic impairment undergoing concurrent TAF prophylaxis.

**Keywords:** Hepatocellular carcinoma (HCC), Hepatitis B virus (HBV), Programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1), Reactivation, Tenofovir alafenamide fumarate (TAF)

## Introduction

Despite the existence of an effective hepatitis B virus (HBV) vaccine and antiviral therapies, HBV-related HCC remains a leading cause of death worldwide, particularly in Asia and Africa [1–3]. More than 350 million people are chronically infected with HBV worldwide [4, 5]. Unfortunately, over 70% of HBV-HCC cases are diagnosed at a late stage, which results in limited treatment options and poor prognosis [6]. Recently, immune checkpoint inhibitors (ICIs) like antibodies for programmed cell death-1 (PD-1), programmed cell death-ligand 1 (PD-L1) and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), have been reported to be the hotspot of HCC immunotherapy, since the interaction between PD-1, CTLA-4, and their ligands (PD-L1 and CD80/86) inhibits T-cell activation. For advanced HCC patients, PD-1/PD-L1 pathway inhibitor in combination with an antiangiogenic therapy has been demonstrated to be an effective treatment regimen [7–10]. However, a high baseline HBV DNA level has always been listed as an exclusion criterion for PD-1/PD-L1 inhibitor-associated therapy in clinical trials, regardless of the antiviral strategies. This is due to the controversial nature of the interaction between HBV load and anti-PD-1/PD-L1 therapy, particularly in HCC patients.

Several studies have shown that HBV reactivation induced by immunosuppressive agents or cytotoxic chemotherapy is a complication in cancer patients with pre-existing HBV infection, especially in those not subjected to continuous antiviral therapy [11–13]. Furthermore, Zhang et al. [14] demonstrated that the absence of antiviral prophylaxis treatment was the only significant risk factor for HBV reactivation following anti-PD-1/PD-L1 immunotherapy. Tenofovir alafenamide fumarate (TAF), a novel prodrug of tenofovir (TFV) that has been approved for the treatment of chronic HBV infection, is characterized by a greater plasma stability and higher renal safety than tenofovir disoproxil fumarate (TDF) [15, 16].

However, to the best of our knowledge, no study has investigated the effects of anti-PD-1 treatment in combination with an antiangiogenic therapy on HBV infection in TAF prophylaxis-subjected individuals. Hence, we conducted a retrospective study to explore the effects of

HBV load on anti-PD-1 in combination with an antiangiogenic therapy and the rate of HBV reactivation and hepatitis during a combined anti-PD-1 and antiangiogenic treatment.


## Methods

### Study design and patients

We performed a retrospective cohort study on unresectable HCC patients who were seropositive for HBsAg and accepted TAF therapy prior to combined anti-PD-1 and antiangiogenic treatment. This study included consecutive patients who were referred to Nanfang Hospital, Southern Medical University in Guangzhou, China, between Jul 2019 and Oct 2021. A total of 108 patients were screened for eligibility according to the following inclusion criteria: (1) pathologically diagnosed with HCC; (2) received at least one cycle of anti-PD-1 therapy; (3) seropositive for HBsAg and had received TAF therapy as a regular antiviral regimen before anti-PD-1 treatment; and (4) with HBV DNA and liver function monitored regularly during the follow-up. Patients were excluded for: (1) the presence of other positive viral markers, including IgM antibodies to the hepatitis A virus, hepatitis C virus (HCV), or hepatitis E virus, IgG antibodies to the hepatitis D virus or HIV; (2) participating in other clinical trials; and (3) not having baseline HBV DNA and HBsAg test results (baseline defined as within 2 weeks prior to initial PD-1 inhibitor therapy). Finally, 70 patients with complete data were included in the current study. Figure 1 shows a flowchart of the patient selection procedure. This study was performed in accordance with the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the ethics committee of the Nanfang Hospital, Southern Medical University. Informed consent was obtained from all the patients prior to their participation.

### Clinical endpoints

Eligible patients were divided into a low HBV DNA group (low group,  $\leq 2000$  IU/ml) and a high HBV DNA group (high group,  $> 2000$  IU/ml) according to the baseline HBV DNA levels. The primary study end point was progression-free survival (PFS), which was defined as the time from the first dose of anti-PD-1 immunotherapy to the first radiological disease progression or death according



to the Response Evaluation Criteria in Solid Tumours (RECIST) criteria, version 1.1. The secondary endpoints included HBV reactivation and HBV-associated hepatitis. HBV reactivation in patients positive for HBsAg was defined according to the American Association for the Study of Liver Diseases 2018 Hepatitis B guidance: (1) a  $\geq 2$  log (100-fold) increase in HBV DNA compared to the baseline level; (2) HBV DNA  $\geq 1000$  IU/mL in a patient with a previously undetectable level [17]. HBV-associated hepatitis was defined as a three-fold or greater increase in serum ALT or AST than the upper limit of a normal value or an absolute increase in serum ALT to more than 100 U/L accompanying or following HBV reactivation [18]. Follow-up computed tomography (CT) or magnetic resonance imaging (MRI) scans were performed 6–12 weeks after anti-PD1 treatment initiation and approximately 3–6 months thereafter. Serum HBV DNA level was measured with the Cobas Taqman HBV Kit (Roche Diagnostics; lower limit of detection: 20 IU/mL) and was also tested at each follow-up visit.

### Statistical analysis

All statistical analyses were performed using the SPSS (version 25, Chicago, NY, USA) and R software (version 3.6.2, <http://www.Rproject.org>). Data were expressed as counts (percentages) for categorical variables, as mean  $\pm$  standard deviation (SD) for quantitative variables

according to normal distribution, and as median (range) for variables with non-normal distribution. Pearson  $\chi^2$  tests or Fisher's exact tests were used to analyse relationships between categorical variables. PFS was performed using the Kaplan–Meier method. Univariate analyses were performed with the log-rank test, and variables with a  $P$  value lower than 0.1 were included in the multivariate analysis. Multivariate analyses were performed using the Cox's proportional hazard regression model. Statistical significance was set at  $P < 0.05$ .

## Results

### Patients' characteristics

The clinical characteristics of the 70 patients with HCC are summarised in Table 1. Accordingly, the mean age was  $52.5 \pm 12.2$ , and 66 (94.3%) patients were male. Regarding relative tumour features, 69 patients (98.5%) had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; 42 (60.0%) had a portal vein tumour thrombus (PVT); 25 (35.7%) had extrahepatic metastasis; 46 (65.7%) had more than 3 tumour lesions; 33 (47.1%) had the largest tumour diameter of over 7 cm; and 30 (47.1%) had an AFP level  $> 400$  ng/mL. All patients received anti-PD-1 in combination with an antiangiogenic therapy, and the antiangiogenic regimens included lenvatinib (58.6%), sorafenib (11.4%), apatinib (7.2%), regorafenib (11.4%), and bevacizumab

**Table 1** Baseline characteristics of the 70 HCC patients receiving anti-PD-1 in combination with antiangiogenic therapy

| Characteristics            | All patients (n = 70) |
|----------------------------|-----------------------|
| Gender                     |                       |
| Male, n (%)                | 66, (94.3)            |
| Female, n (%)              | 4, (5.7)              |
| Age (y) <sup>Δ</sup>       | 52.5 ± 12.2           |
| BCLC stage                 |                       |
| B, n (%)                   | 18, (25.7)            |
| C, n (%)                   | 52, (74.3)            |
| Child–Pugh class           |                       |
| A, n (%)                   | 55, (78.6)            |
| B, n (%)                   | 15, (21.4)            |
| ECOG performance           |                       |
| 0, n (%)                   | 50, (71.4)            |
| 1, n (%)                   | 19, (27.1)            |
| 2, n (%)                   | 1, (1.4)              |
| Portal vein tumor thrombus |                       |
| Yes, n (%)                 | 42, (60.0)            |
| No, n (%)                  | 28, (40.0)            |
| Extrahepatic metastasis    |                       |
| Yes, n (%)                 | 25, (35.7)            |
| No, n (%)                  | 45, (64.3)            |
| Tumor number               |                       |
| < 3, n (%)                 | 24, (34.3)            |
| ≥ 3, n (%)                 | 46, (65.7)            |
| Largest tumor diameter     |                       |
| < 7 cm, n (%)              | 37, (52.9)            |
| ≥ 7 cm, n (%)              | 33, (47.1)            |
| α-Fetoprotein level        |                       |
| < 400 ng/mL, n (%)         | 40, (57.1)            |
| ≥ 400 ng/mL, n (%)         | 30, (42.9)            |
| Antiangiogenic drug        |                       |
| Lenvatinib, n (%)          | 41, (58.6)            |
| Sorafenib, n (%)           | 8, (11.4)             |
| Apatinib, n (%)            | 5, (7.2)              |
| Regorafenib, n (%)         | 8, (11.4)             |
| Bevacizumab, n (%)         | 8, (11.4)             |
| ALT (U/L)*                 | 31.5 (9.0, 146.0)     |
| AST (U/L)*                 | 46.0 (14.0, 225.0)    |
| Albumin (g/L) <sup>Δ</sup> | 36.7 ± 4.7            |
| Total bilirubin (mmol/L)*  | 15.2 (5.2, 55.8)      |
| PLT (10 <sup>9</sup> /L)*  | 151.5 (34.0, 695.0)   |
| PT (s) <sup>Δ</sup>        | 11.7 ± 1.3            |
| HBV DNA                    |                       |
| ≤ 2000 IU/mL, n (%)        | 48, (68.6)            |
| > 2000 IU/mL, n (%)        | 22, (31.4)            |
| HBsAg (IU/mL)*             | 403.9 (0.1, 7026.0)   |
| HBeAg                      |                       |
| Positive, n (%)            | 9, (12.9)             |
| Negative, n (%)            | 61, (87.1)            |

**Table 1** (continued)

BCLC Barcelona-clinic liver cancer, ECOG Eastern cooperative oncology group, ALT alanine aminotransferase, AST aspartate aminotransferase, PLT platelet count, PT prothrombin time

<sup>Δ</sup> Normal distribution (mean ± Standard deviation); \*non-normal distribution [median, (minimum, maximum)]

(11.4%). At baseline, 48 patients (68.6%) had a low HBV DNA level (baseline viral load ≤ 2,000 IU/mL), while 22 patients (31.4%) had a high HBV DNA level (baseline viral load > 2,000 IU/mL). In addition, the median HBsAg level was 403.9 (0.1, 7026.0) and 87.1% of patients were HBeAg-negative.

### Tumour responses

Tumour responses are shown in Table 2. Of all the included patients, 1 achieved a complete response (CR) (1.4%), 14 achieved a partial response (PR) (20.0%), and 36 patients had a stable disease (SD) (51.4%), resulting in an objective response rate (ORR) of 21.4% and a disease control rate (DCR) of 72.9%. The subgroup analysis revealed that ORRs in patients with low and high baseline HBV DNA levels were 22.9% and 18.2%, respectively (Fisher's exact test,  $P=0.761$ ), while the DCRs were 75.0% and 68.2%, respectively ( $\chi^2=0.355$ ;  $P=0.552$ ).

### Baseline HBV loads do not affect PFS

During treatment, 35 patients (50.0%) had a progressive disease. The median PFS time was 7.5 months. There was no significant difference in PFS between patients with a baseline HBV DNA level ≤ 2000 IU/mL and those with a DNA level > 2000 IU/mL ( $\chi^2=0.075$ ;  $P=0.784$ ) (Fig. 2). To further identify whether baseline variables, especially HBV loads, affect PFS, univariate and multivariate Cox analyses were conducted. Univariate Cox regression analysis identified the following factors that affected PFS: tumour lesion number < 3 (OR 0.428, 95% CI, 0.187–0.982;  $P=0.045$ ), AFP level < 400 ng/mL (OR 0.448, 95% CI, 0.227–0.883;  $P=0.020$ ), and TBIL (OR 1.036, 95% CI, 1.006–1.066;  $P=0.018$ ). We then included these significant factors in a multivariate analysis, but found no independent predictive factors that affected PFS (Fig. 3).

### HBV reactivation and hepatitis


During the follow-up period, only two of the 70 patients (2.9%) experienced HBV reactivation. The details of the 2 patients with HBV reactivation are shown in Fig. 4. Briefly, both were male and had undetectable baseline HBV DNA levels. Patient 1 received atezolizumab in combination with bevacizumab and developed HBV reactivation at the 2nd visit (after 5 doses of atezolizumab). The patient's HBV DNA level was 3162.3 IU/mL at diagnosis of HBV reactivation, achieved the highest

**Table 2** Best tumor responses of patients with low and high baseline HBV DNA level

| Tumor response             | All patients (n = 70) | Baseline HBV DNA ≤ 2000 IU/mL (n = 48) | Baseline HBV DNA > 2000 IU/mL (n = 22) |
|----------------------------|-----------------------|--|--|
| Complete response (CR)     | 1 (1.4)               | 1 (2.1)                                | 0                                      |
| Partial response (PR)      | 14 (20.0)             | 10 (20.8)                              | 4 (18.2)                               |
| Stable disease (SD)        | 36 (51.4)             | 25 (52.1)                              | 11 (50.0)                              |
| Progressive disease (PD)   | 19 (27.1)             | 12 (25.0)                              | 7 (31.8)                               |
| ORR (CR + PR) <sup>Δ</sup> | 15 (21.4)             | 11 (22.9)                              | 4 (18.2)                               |
| DCR (CR + PR + SD)*        | 61 (72.9)             | 36 (75.0)                              | 15 (68.2)                              |

ORR objective response rate, DCR disease control rate

<sup>Δ</sup> Fisher’s exact test, *P* = 0.761; \*Pearson  $\chi^2$  = 0.355, *P* = 0.552




level at the 3rd visit (3622.8 IU/mL), but fell to 205.1 IU/mL, < 10 IU/mL and undetectable at the 4th, 5th and 6th visit, respectively. The peak ALT level was 68 U/L during the follow-up. Patient 2 received tislelizumab in combination with lenvatinib and developed HBV reactivation at the 2nd visit (after 6 doses of tislelizumab). The patient’s HBV DNA level was 2417 IU/mL at diagnosis of HBV reactivation (the highest level), but fell to 20.2 IU/mL and undetectable at the 4th and 5th visit, respectively, with a peak ALT level of 49 U/L. Accordingly, both patients 1 and 2 exhibited a brief increase in HBV DNA

levels without HBV-associated ALT elevation. None of the patients experienced immunotherapy disruption during the follow-up. In addition, 16 of the 70 patients (22.9%) experienced ALT elevation; however, all of these were considered cases of immune-related hepatitis as none of the 16 patients suffered from HBV reactivation.

**Discussion**


To date, it has been confirmed that the HBV DNA level is positively correlated with the up-regulated expression of PD-1 on T cells, which is closely linked to the formation



**Fig. 3** Univariate and multivariate cox analyses of progression-free survival (PFS) stratified by baseline characteristics

of HCC immunosuppressive microenvironment [19, 20]. The PD-1/PD-L1 axis also plays an important role in HBV replication [21]. Recently, the combination regimens of PD-1/PD-L1 inhibitor and an antiangiogenic therapy have been proven to be an optimal treatment for advanced HCC [7, 8, 22, 23]. However, the interaction between HBV load and anti-PD-1/PD-L1 therapy

remains controversial, particularly in patients who do not receive a continuous antiviral therapy. Several studies have reported high HBV load as a risk factor for HBV reactivation and hepatic impairment during anti-PD-1/PD-L1 therapy [24, 25], while other reports demonstrated that PD-1/PD-L1 inhibitors can be safe and effective in cancer patients with either chronic HBV or



HCV infection [26, 27]. Different antiviral agents, such as lamivudine (LAM) or adefovir dipivoxil (ADV), may account for the controversial results in studies reporting HBV load to be a risk factor for HBV reactivation. However, there is no data demonstrating this issue, since the most commonly used agent was entecavir (ETV) or tenofovir (TDF) in the currently reported studies, where LAM and ADV were no longer recommended as first-line anti-viral regimens. Most of the relevant studies did not explore whether antiviral therapy can improve the efficacy and safety of anti-PD-1 treatment in combination with an antiangiogenic therapy. In the current study, we found that baseline HBV load did not affect the prognosis of HCC patients receiving anti-PD-1 combined with an antiangiogenic therapy, while PD-1 inhibitors did not aggravate HBV reactivation and hepatic impairment in patients given TAF prophylaxis.

Since evidence regarding whether HBV infection affects the prognosis of HCC patients receiving anti-PD-1 based therapy is scarce, patients with a high baseline HBV DNA level were always excluded from clinical trials regardless of the antiviral strategies utilized, limiting their efficiency and generalizability. In the KETNOTE-224 study,

tumour response was comparable between patients with and without HBV/HCV infection [27]. Similarly, the CheckMate 040 study reported similar tumour responses among patients with advanced HCC, irrespective of HCC aetiology [26]. However, patients with a higher baseline HBV DNA level (usually >500 IU/mL or >2000 IU/mL) were excluded, and whether baseline HBV DNA level affected the clinical prognosis of HCC patients receiving anti-PD-1 based therapy was not assessed in the above clinical trials. In a retrospective study in China, the baseline HBV load was found to have no significant impact on the prognostic outcomes or rates of hepatic impairment during anti-PD-1 blockade [28]. According to our results, similar ORR and DCR were observed in patients with low and high baseline HBV DNA levels. In addition, there was no significant difference in PFS between patients with a higher or lower baseline HBV loads. Importantly, our data highlight that HBV load may not affect the prognosis of HCC patients receiving anti-PD-1 therapy combined with an antiangiogenic therapy.

Whether PD-1 inhibitors aggravate HBV reactivation and hepatic impairment is another concern of anti-PD-1-based therapies. In a phase Ib study comparing

nivolumab with and without an HBV therapeutic vaccine, in virally suppressed patients with HBeAg (–) chronic HBV, PD-1 inhibitor was demonstrated to be well tolerated and led to HBsAg decline in most patients [29]. In a study comparing HBV reactivation between patients with low and high HBV DNA loads, who were undergoing anti-PD-1 blockade treatment, similar incidences of HBV reactivation and HBV-associated hepatitis were observed [30]. In the current study, only 2 of the 70 patients (2.9%) experienced HBV reactivation, which was a lower rate compared to patients with other cancer types in another study [14]. The reason for this discrepancy may be that all patients in our study simultaneously received TAF prophylaxis. Continuous and effective antiviral treatment was shown to improve the prognosis of HCC patients receiving anti-PD-1 blockade with high viral loads in our previous study (recently accepted article, <https://doi.org/10.21037/atm-21-3020>). Nevertheless, the specific role of TAF in the protection against HBV reactivation or hepatic impairment has not been elucidated, since TAF has been proven to have a greater plasma stability and higher renal safety than TDF. In addition, we did not observe any cases of HBV-related hepatic impairment during the follow-up period. Taken together, we suggest that HBV-HCC patients accept first-line antiviral prophylaxis such as TAF before and during the period of anti-PD-1-based therapy.

The current study is not free from certain limitations. First, this single-arm study was designed retrospectively, which may have caused bias in the selection of patients. The implications of this study need to be verified by future clinical studies with larger sample sizes. Second, the overall survival (OS) data were not included in the analysis, as the follow-up period was not long enough, and only two patients died until the observation deadline. Finally, patients with HCV infection were excluded from the final analysis, and the influence of HCV loads on these patients remains unclear.

In conclusion, our study provides evidence that baseline HBV loads do not affect the prognosis of HCC patients receiving anti-PD-1 in combination with antianagenic therapy, while PD-1 inhibitors do not aggravate HBV reactivation and hepatic impairment in patients given TAF prophylaxis. However, as this was a non-randomized retrospective study, our data should not be taken as non-biased or used to guide clinical decisions without a further proof derived from prospective clinical trials. Besides, future prospective studies should also pay attention to the interaction between HBV reactivation and the combination therapy of anti-PD-1 and anti-CTLA-4, since trials are ongoing to explore the possibility of CTLA-4 in combination with anti-PD-1/PD-L1.

## Abbreviations

HBV: Hepatitis B virus; PD-1: Programmed cell death-1; TAF: Tenofovir alafenamide fumarate; PFS: Progression-free survival; ORRs: Objective response rates; DCRs: Disease control rates; PD-L1: Programmed cell death-ligand 1; TDF: Tenofovir disoproxil fumarate; HCV: Hepatitis C virus; RECIST: Response Evaluation Criteria in Solid Tumours; CT: Computed tomography; MRI: Magnetic resonance imaging; ECOG: Eastern Cooperative Oncology Group; PVTT: Portal vein tumour thrombus; CR: Complete response; PR: Partial response; SD: Stable disease; OS: Overall survival.

## Acknowledgements

Not applicable.

## Author contributions

JC and GY conceived and designed the study. XH, RL, QL and MZ participated in the acquisition of the data. GY participated in analysis, or interpretation of the data. JC and GY participated in the drafting of the article or critical revision for important intellectual content. XH, RL, GY and JC contribute to the revision of article. All authors read and approved the final version of the manuscript.

## Funding

This study was partly supported by grants from the National Natural Science Foundation of China (82102879), the Natural Science Foundation of Guangdong Province (2021A1515012518), the Postdoctoral Research Foundation of China (No. 2021M691468). The funding agencies had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

## Availability of data and materials

The data that support the findings of this study are available from the corresponding author upon reasonable request.

## Declarations

### Ethics approval and consent to participate

The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All procedures performed in this study involving human participants were in accordance with the 1975 Declaration of Helsinki. The Ethical Committee of Nanfang Hospital, Southern Medical University granted approval for this study, and written informed consent was obtained from each patient before the procedure.

### Consent for publication

Not applicable.

### Competing interests

The authors have no conflicts of interest to disclose.

Received: 21 April 2022 Accepted: 7 July 2022

Published online: 14 July 2022

## References

1. EASL Clinical Practice Guidelines. Management of hepatocellular carcinoma. *J Hepatol*. 2018;69(1):182–236. <https://doi.org/10.1016/j.jhep.2018.03.019>.
2. Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. *Hepatology*. 2018;67(1):358–80. <https://doi.org/10.1002/hep.29086>.
3. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A, Global cancer statistics 2018. GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2018. <https://doi.org/10.3322/caac.21492>.
4. Nguyen MH, Wong G, Gane E, Kao JH, Dusheiko G. Hepatitis B virus: advances in prevention, diagnosis, and therapy. *Clin Microbiol Rev*. 2020. <https://doi.org/10.1128/CMR.00046-19>.

5. Wong M, Huang J, George J, et al. The changing epidemiology of liver diseases in the Asia-Pacific region. *Nat Rev Gastroenterol Hepatol*. 2019;16(1):57–73. <https://doi.org/10.1038/s41575-018-0055-0>.
6. Singal AG, Lampertico P, Nahon P. Epidemiology and surveillance for hepatocellular carcinoma: new trends. *J Hepatol*. 2020;72(2):250–61. <https://doi.org/10.1016/j.jhep.2019.08.025>.
7. Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. *N Engl J Med*. 2020;382(20):1894–905. <https://doi.org/10.1056/NEJMoa1915745>.
8. Finn RS, Zhu AX. Evolution of Systemic Therapy for Hepatocellular Carcinoma. *Hepatology*. 2020. <https://doi.org/10.1002/hep.31306>.
9. Chen J, Hu X, Li Q, et al. Effectiveness and safety of toripalimab, camrelizumab, and sintilimab in a real-world cohort of hepatitis B virus associated hepatocellular carcinoma patients. *Ann Transl Med*. 2020;8(18):1187. <https://doi.org/10.21037/atm-20-6063>.
10. Yuan G, Cheng X, Li Q, et al. Safety and efficacy of camrelizumab combined with apatinib for advanced hepatocellular carcinoma with portal vein tumor thrombus: a multicenter retrospective study. *Oncotargets Ther*. 2020;13:12683–93. <https://doi.org/10.2147/OTT.S286169>.
11. Paul S, Saxena A, Terrin N, Viveiros K, Balk EM, Wong JB. Hepatitis B virus reactivation and prophylaxis during solid tumor chemotherapy: a systematic review and meta-analysis. *Ann Intern Med*. 2016;164(1):30–40. <https://doi.org/10.7326/M15-1121>.
12. Chen C, Zhang F, Zhou N, et al. Efficacy and safety of immune checkpoint inhibitors in advanced gastric or gastroesophageal junction cancer: a systematic review and meta-analysis. *Oncotargets Ther*. 2019;8(5):e1581547. <https://doi.org/10.1080/2162402X.2019.1581547>.
13. Burns EA, Muhsen IN, Anand K, et al. Hepatitis B virus reactivation in cancer patients treated with immune checkpoint inhibitors. *J Immunother*. 2021;44(3):132–9. <https://doi.org/10.1097/CJI.0000000000000358>.
14. Zhang X, Zhou Y, Chen C, et al. Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition. *J Immunother Cancer*. 2019;7(1):322. <https://doi.org/10.1186/s40425-019-0808-5>.
15. Agarwal K, Brunetto M, Seto WK, et al. 96weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. *J Hepatol*. 2018;68(4):672–81. <https://doi.org/10.1016/j.jhep.2017.11.039>.
16. EASL. 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. *J Hepatol*. 2017;67(2):370–98. <https://doi.org/10.1016/j.jhep.2017.03.021>.
17. Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. *Hepatology*. 2018;67(4):1560–99.
18. Huang H, Li X, Zhu J, et al. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial. *JAMA*. 2014;312(23):2521–30. <https://doi.org/10.1001/jama.2014.15704>.
19. Lim CJ, Lee YH, Pan L, et al. Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma. *Gut*. 2019;68(5):916–27. <https://doi.org/10.1136/gutjnl-2018-316510>.
20. Ho WJ, Danilova L, Lim SJ, et al. Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma. *J Immunother Cancer*. 2020. <https://doi.org/10.1136/jitc-2019-000394>.
21. Xuan HN, Thi MHP, Dinh TB, et al. Association of PD-L1 gene polymorphisms and circulating sPD-L1 levels with HBV infection susceptibility and related liver disease progression. *Gene*. 2022;806: 145935. <https://doi.org/10.1016/j.gene.2021.145935>.
22. Xu J, Shen J, Gu S, et al. Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): a nonrandomized, open-label. Phase II Trial Clin Cancer Res. 2021;27(4):1003–11. <https://doi.org/10.1158/1078-0432.CCR-20-2571>.
23. Deng H, Kan A, Lyu N, et al. Dual vascular endothelial growth factor receptor and fibroblast growth factor receptor inhibition elicits antitumor immunity and enhances programmed cell death-1 checkpoint blockade in hepatocellular carcinoma. *Liver Cancer*. 2020;9(3):338–57. <https://doi.org/10.1159/000505695>.
24. Trehanpati N, Vyas AK. Immune regulation by T regulatory cells in hepatitis B virus-related inflammation and cancer. *Scand J Immunol*. 2017;85(3):175–81. <https://doi.org/10.1111/sji.12524>.
25. Loomba R, Liang TJ. Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions. *Gastroenterology*. 2017;152(6):1297–309. <https://doi.org/10.1053/j.gastro.2017.02.009>.
26. El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. *Lancet Oncol*. 2017;389(10088):2492–502. [https://doi.org/10.1016/S1470-6736\(17\)31046-2](https://doi.org/10.1016/S1470-6736(17)31046-2).
27. Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. *Lancet Oncol*. 2018;19(7):940–52. [https://doi.org/10.1016/S1470-2045\(18\)30351-6](https://doi.org/10.1016/S1470-2045(18)30351-6).
28. Sun X, Hu D, Yang Z, et al. Baseline HBV loads do not affect the prognosis of patients with hepatocellular carcinoma receiving anti-programmed cell death-1 immunotherapy. *J Hepatocell Carcinoma*. 2020;7:337–45. <https://doi.org/10.2147/JHC.S278527>.
29. Gane E, Verdon DJ, Brooks AE, et al. Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: a pilot study. *J Hepatol*. 2019;71(5):900–7. <https://doi.org/10.1016/j.jhep.2019.06.028>.
30. He MK, Peng C, Zhao Y, et al. Comparison of HBV reactivation between patients with high HBV-DNA and low HBV-DNA loads undergoing PD-1 inhibitor and concurrent antiviral prophylaxis. *Cancer Immunol Immunother*. 2021. <https://doi.org/10.1007/s00262-021-02911-w>.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

### Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)

